| CAS NO: | 2070009-41-3 |
| 包装 | 价格(元) |
| 500 μg | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| Cas No. | 2070009-41-3 |
| 别名 | 瑞舒伐他汀-D6二钠盐 |
| Canonical SMILES | O[C@@H](C[C@H](CC([O-])=O)O)/C=C/C(C(C1=CC=C(F)C=C1)=NC(N(C)[S](C)(=O)=O)=N2)=C2C(C([2H])([2H])[2H])C([2H])([2H])[2H].[Na+] |
| 分子式 | C22H21D6FN3O6S.Na |
| 分子量 | 509.6 |
| 溶解度 | Methanol: Soluble |
| 储存条件 | Store at 4°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Rosuvastatin-d6is intended for use as an internal standard for the quantification of rosuvastatin by GC- or LC-MS. Rosuvastatin is an HMG-CoA reductase inhibitor (IC50= 5 nM).1,2It is a fully-synthetic inhibitor that is designed to maximize the points of contact with, and inhibition of, HMG-CoA reductase.1Formulations containing rosuvastatin reduce low-density lipoprotein and C-reactive protein and increase high-density lipoprotein in humans.3,4 1.Istvan, E.S., and Deisenhofer, J.Structural mechanism for statin inhibition of HMG-CoA reductaseScience292(5519)1160-1164(2001) 2.Tobert, J.A.Lovastatin and beyond: The history of the HMG-CoA reductase inhibitorsNat. Rev. Drug Discov.2(7)517-526(2003) 3.Asztalos, B.F., Maulf, F.L., Dallal, G.E., et al.Comparison of the effects of high doses of Rosuvastatin versus Atorvastatin on the subpopulations of high-density lipoproteinsAm. J. Cardiol.99(5)681-685(2007) 4.Rubba, P., Marotta, G., and Gentile, M.Efficacy and safety of rosuvastatin in the management of dyslipidemiaVasc. Health Risk Manag.5(1)343-352(2009) |
m.cnreagent.com